26-03-11_Panel+discussion+at+the+AI+Circular+Economy+Conference+2026

The AI Circular Economy Conference 2026, organised by nova-Institute, brought together 116 participants from 15 countries in Cologne and online to explore the transformation of the chemical and materials industry supported and accelerated by artificial intelligence.

SLAS-EU26-Banner_16x9

Featuring 100 exhibitors, keynote and podium speakers, behind-the-scenes access to a leading biotech campus, and a rich ­networking program, SLAS Europe 2026 is designed for professionals at every stage of their careers.

Biotech is entering its automated era. Robots run assays, AI designs molecules, and data drives decisions. For young scientists, the question is not survival, it is leadership. Will you adapt to the new lab, or help define it?

Austria’s biotech sector is gaining momentum as the EU Bio­tech Act opens new opportunities. BIOTECH AUSTRIA and EuropaBio join forces to strengthen innovation, competitiveness, and Europe’s role as a global biotech leader.

elrig

Discover ELRIG’s quarter two events – three focused scientific meetings showcasing the newest technologies, models, and strategies redefining drug discovery. Join global experts advancing complex cellular systems, automation, and innovative target screening.

The Basel-based pharmaceutical group Roche is pressing ahead with its digital strategy and setting new benchmarks for the industry. Together with NVIDIA, the company is building an “AI factory” that will become the largest computing infrastructure ever announced by a pharma company. In the race among pharma majors, Roche has now overtaken the supercomputer recently unveiled by Eli Lilly.

TW26_Infografik_Advertorial_115x65mm--2

Research and innovation are considered key resources for European competitiveness – and essential location factors for research-intensive industries such as the Life Sciences. The European Union is increasingly responding to this finding with a multifaceted catalogue of regulations and measures: alongside horizontal and sector-specific legal frameworks, data-law infrastructures as well as operational initiatives are being introduced, which are intended to accelerate procedures and facilitate the translation of research into healthcare delivery and into the market.

EBG2026

The “16th European Biotechnology Science & Industry Guide 2026” presents the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe.

Chesterford Research Park

UK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares to start its first clinical trial in cancer in mid-2026. The new financing brings total capital committed to the Cambridge-based company to more than $95 million, following its $11 million launch round in April 2021 and a seed extension that took total seed financing to $45 million in August 2021.

The new Dortmund-based biotech iDEL Therapeutics has launched with a €9 million seed round to develop a new class of cancer therapies. The financing was led by BiomedVC, with participation from NRW.Venture, Gründerfonds Ruhr and the KHAN Technology Transfer Fund II.